VER-01 Sealing Sutured Cranial Dural Repair Study

Phase 3

Recruiting

• Conditions: Elective craniotomy or decompressive craniectomy surgery in supratentorial or posterior fossa

• Registration Number: JPRN-jRCT2031230364
• Lead Sponsor: Deura Imari

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2023-09-27
• Last Update Posted: 22 January 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 130

Inclusion Criteria

Pre-operative
1.Subjects undergoing an elective craniotomy or decompressive craniectomy surgery in supratentorial or posterior fossa
2.At least 18 years of age at the time of informed consent.
3.Willingness to comply with the protocol.
4.Willingness to give consent before all study-related activities.

Intra-operative
1.Surgical wound classification Class I. Superficial penetration of mastoid air cells during partial mastoidectomy is permitted.
2.The cuff of native dura along the craniotomy edge on each side is adequate, based on judgement of principal investigator or sub-investigator, to facilitate suturing and to allow for sufficient surface area for adherence of the sealant
3.Presence of intra-operative spontaneous cerebrospinal fluid (CSF) leakage following sutured dural closure or after Valsalva maneuver. If a spontaneous leak is apparent immediately after dural closure, no Valsalva maneuver will be performed.

Exclusion Criteria

Pre-operative
1.Subjects with a cranial dural lesion from a recent surgery that still has the potential for CSF leakage.
2.Chemotherapy scheduled within 30 days prior to enrollment or scheduled within 7 days following surgery.
3.Radiation therapy to the head scheduled within 30 days prior to enrollment or scheduled within 7 days following surgery.
4.Corticosteroids on a chronic basis (more than 6 weeks) unless treatment is discontinued 4 weeks prior to planned surgery
5.Subjects who have intolerance to any of the components of the investigational or comparator products (including bovine-derived ingredients).
6.Subjects who are not willing to use blood products.
7.Subjects with any other pre-operative finding identified by the surgeon that in their opinion, may affect the primary or secondary endpoints such as severely altered renal or hepatic function, compromised immune system, autoimmune disease or uncontrolled/poorly controlled diabetes with the risk of wound healing complication.
8.Subjects who have hydrocephalus (unless hydrocephalus caused by posterior fossa pathology or incompletely open cerebrospinal fluid pathways is treated in this study)
9.Subjects with traumatic injuries to the head with damage to the dura and/or with an existing shunt or drain for decompression.
10.Subjects of childbearing potential with a positive pregnancy test or those who intend to become pregnant during the clinical study period.
11.Subjects who are breastfeeding.
12.Subjects who have participated in or will participate in another clinical trial of another a test drug/device within 30 days of a surgery of the clinical trial.
13.Subjects judged to be inappropriate by the principal investigator or sub-investigator.

Intra-operative
1.Unintentional dural tears during craniotomy/ decompressive craniectomy that cannot be suture repaired.
2.Subject has a gap between durotomy edges of greater than 2 mm after primary dural closure.
3.Use of implants made of synthetic materials that cannot be sutured to dura, shunts, ventricular and subdural drains.
4.Intersecting durotomy scars in the surgical path from a previous operation that cannot be completely removed by the planned dural resection.
5.Placement of Gliadel Wafers
6.Two or more separate dural defects.
7.Subjects who have serious complication in surgeries requiring emergency resuscitation or changing of planned surgeries.
8.Subjects judged to be inappropriate by the principal investigator or sub-investigator.

Study & Design

• Study Type: Interventional
• Study Design: Not specified